Diabetes Research · Vol. 2, No. 2 · 2016 · pp. e10–e13 · e-ISSN 2379-6375

Wellness Fasting and Hyperketosis

Shaw Watanabe

Life Science Promotion Foundation, 25-3-1004, Daikyo-cho, Shinjuku-ku, Tokyo 160-0005, JapanJapan

DOI: https://doi.org/10.17140/droj-2-e007 · Published 2016-09-26 · Licence: https://creativecommons.org/licenses/by/4.0 · © 2016 The Author(s)

Also available as PDF (figures and tables appear in the PDF).

Abstract

Ketoacidosis is sometimes a lethal complication of diabetes mellitus.1-3 Ketone bodies are considered to be the toxic elements of ketoacidosis. Wilder3 considered that the threshold of ketogenesis (i.e. the maximal ratio compatible with the oxidation of the ketogenic compounds) was reached when the number of ketogenic molecules just equaled the number of glucose molecules. Each glucose molecule being ketolytic for 2 molecules of acetoacetic acid, the ratio is 2:1. As the glucose concentration exceeds 3 mM in the blood, 3-6 mM of ketone bodies in the blood would be considered to reach hyperketosis. Ketogenic food containing a high proportion of fat has been successfully used to treat epileptic fits resistant to medication.4 In a typical epilepsy diet, fat accounts for 90% of the energy intake. Such meals bring about changes in the enterobacterial flora.5

Acknowledgement

The author thanks Dr. Philippe Calain for English editing.

References

  1. StojanovicVIhleS. Role of beta-hydroxybutyric acid in diabetic ketoacidosis: A review. Can Vet J. 2011; 52(4): 426-430. Web site. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058661/. Accessed September 24, 2016
  2. LaffelL. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999; 15(6): 412-426. doi: 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-810.1002/(sici)1520-7560(199911/12)15:6 https://doi.org/10.1002/(sici)1520-7560(199911/12)15:6
  3. WilderRMWinterMD. The threshold of ketogenesis. J Biol Chem. 1922; 52: 393-401. Web site. http://www.jbc.org/content/52/2/393.short. Accessed September 24, 2016
  4. KangHCChungDEKimDWKimHD. Early- and late- onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004; 45(9): 1116-1123. doi: 10.1111/j.0013-9580.2004.10004.x10.1111/j.0013-9580.2004.10004.x https://doi.org/10.1111/j.0013-9580.2004.10004.x
  5. ChuDMAntonyKMMaJ. The early infant gut microbiome varies in association with a maternal high-fat diet. Genome Med. 2016; 8(1): 77. doi: 10.1186/s13073-016-0330-z10.1186/s13073-016-0330-z https://doi.org/10.1186/s13073-016-0330-z
  6. WatanabeSHirakawaAAoeSFukudaKMunetaT. Basic ketone engine and booster glucose engine for energy production. Diabetes Res Open J. 2016; 2(1): 14-23. doi: 10.17140/DROJ-2-12510.17140/droj-2-125 https://doi.org/10.17140/droj-2-125
  7. Cahill GF Jr. Fuel metabolism in starvation. Ann Rev Nutr. 2006; 26: 1-22. doi: 10.1146/annurev.nutr.26.061505.111258 https://doi.org/10.1146/annurev.nutr.26.061505.111258
  8. GoldblattMW. Observation on the effect of various carbohydrates on the ketosis of starvation in human subjects. Biochem J. 1925; 19: 948-958. Web site. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1259284/. Accessed September 24, 2016
  9. HirakawaAWatanabeSTanakaK. Koda’s fasting therapy: Energy balance and intestinal bacterial flora. Adv Food Technol Nutr Sci Open J. 2015: 1(5): 112-123. doi: 10.17140/AFTNSOJ-1-12010.17140/aftnsoj-1-120 https://doi.org/10.17140/aftnsoj-1-120
  10. AagaardKPetrosinoJKeitelW. The human microbiome project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J Off Publ Fed Am Soc Exp Biol. 2013; 27: 1012-1022. doi: 10.1096/fj.12-22080610.1096/fj.12-220806 https://doi.org/10.1096/fj.12-220806
  11. VaelCVerhulstSLNelenVGoossensHDesagerKN. Intestinal microflora and body mass index during the first three years of life: An observational study. Gut Pathog. 2011; 3(1): 8. doi: 10.1186/1757-4749-3-810.1186/1757-4749-3-8 https://doi.org/10.1186/1757-4749-3-8
  12. TuohyKRioDD. Diet-Microbe Interactions in the Gut: Effects on Human Health and Disease. 1st ed. CA, USA: Elsevier; 2014
  13. GorvitovskaiaAHolmesSPHuseSM. Interpreting prevotella and bacteroides as biomarkers of diet and lifestyle. Microbiome. 2016; 4: 15. doi: 10.1186/s40168-016-0160-710.1186/s40168-016-0160-7 https://doi.org/10.1186/s40168-016-0160-7
  14. HayashiHSakamotoMBennoY. Fecal microbial diversity in a strict vegetarian as detemined by molecular analysis and cultivation. Microbiol Immunol. 2002; 46: 819-831. doi: 10.1111/j.1348-0421.2002.tb02769.x10.1111/j.1348-0421.2002.tb02769.x https://doi.org/10.1111/j.1348-0421.2002.tb02769.x
  15. KurakawaTOgataKMatsudaK. Diversity of intestinal clostridium coccoides group in the Japanese population, as demonstragted by reverse transription-quantitative PCR. PLOS One. 2015. doi:
  16. MoorkothDNampoothiriKM. Production and characterization of poly(3-hydroxy butyrate-co-3 hydroxyvalerate)(PHBV) by a novel holotolerant mangrove isolate. Bioresour Technol.2016; 201: 253-260. doi: 10.1016/j.biortech.2015.11.04610.1016/j.biortech.2015.11.046 https://doi.org/10.1016/j.biortech.2015.11.046
  17. RobinsonAMWilliamsonDH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Review. 1980; 60: 143-187. Web site. http://physrev.physiology.org/content/60/1/143. Accessed September 24, 2016
  18. Newman JC, Verdin E. β-hydroxybutyrate: Much more than a metabolite. Diabetes Res Clin Pract. 2014; 106(2): 173-181. doi: 10.1016/j.diabres.2014.08.009 https://doi.org/10.1016/j.diabres.2014.08.009
  19. DelcuveGPKhanDHDavieJR. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin Epigenetics. 2012; 4(1): 5. doi: 10.1186/1868-7083-4-510.1186/1868-7083-4-5 https://doi.org/10.1186/1868-7083-4-5
  20. ShimazuTHirscheyMDNewmanJ. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013; 339(6116): 211-214. doi: 10.1126/science.122716610.1126/science.1227166 https://doi.org/10.1126/science.1227166
  21. YoumYHNguyenKYGrantRW. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21(3): 263-269. doi: 10.1038/nm.380410.1038/nm.3804 https://doi.org/10.1038/nm.3804
  22. KeslSLPoffAMWardNP. Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Nutr Metab (Lond). 2016; 13(1): 9
  23. ZhangJCaoQLiS. 3-Hydroxybutyrate methyl ester as a potential protenction mechanism. Biomaterials. 2013; 34(30): 7552-7562. doi: 10.1016/j.biomaterials.2013.06.04310.1016/j.biomaterials.2013.06.043 https://doi.org/10.1016/j.biomaterials.2013.06.043
  24. CoxPJKirkTAshmoreT. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metabolism. 2016; 24: 256-268. doi: 10.1016/j.cmet.2016.07.01010.1016/j.cmet.2016.07.010 https://doi.org/10.1016/j.cmet.2016.07.010
  25. FloegelA. Low carbohydrate-high protein diets. BMJ. 2012; 344: e3801. doi: 10.1136/bmj.e380110.1136/bmj.e3801 https://doi.org/10.1136/bmj.e3801
  26. FungTTvan DamRMHankinsonSE. Low-carbohydrate diets and studies. Ann Intern Med. 2010; 153(5): 289-298. doi: 10.1059/0003-4819-153-5-201009070-0000310.1059/0003-4819-153-5-201009070-00003 https://doi.org/10.1059/0003-4819-153-5-201009070-00003
  27. LagiouPSandinSWeiderpassE. Low carbohydrate-high protein diet and mortality in a cohort of Swedish women. J Intern Med. 2007; e261: 366-374. doi: 10.1111/j.1365-2796.2007.01774.x10.1111/j.1365-2796.2007.01774.x https://doi.org/10.1111/j.1365-2796.2007.01774.x
  28. EbeK. Diabetic diet and carobohydrate restricted diet: Safety and risk. Clin Funct Nutriol. 2016; 8(5): 243-246
  29. VeechRL. The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids. 2014; 70(3): st 10.1371/journal.pone.0126226 doi: 10.1186/s12986-016-0069-y drug against Alzheimer’s disease via mitochondria all-cause and cause-specific mortality: Two cohort 309-319. doi: 10.1016/j.plefa.2003.09.00710.1371/journal.pone.0126226 https://doi.org/10.1371/journal.pone.0126226
  30. BonuccelliGTsirigosAWhitaker-MenezesD. Ketones and lactate cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010; 9(17): 3506-3514. doi: 10.4161/cc.9.17.1273110.4161/cc.9.17.12731 https://doi.org/10.4161/cc.9.17.12731
  31. OleksyszynJ. The complete control of glucose level utilizing the composition of ketogenic diet with the gluconeogenesis inhibitor, the anti-diabetic drug methormin, as a potential anti-cancer therapy. Med Hypotheses. 2011; 77(2): 171-173. doi: 10.1016/j. mehy.2011.04.001 “fuel” tumor growth and metastasis: Evidence that10.1016/j.mehy.2011.04.001 https://doi.org/10.1016/j.mehy.2011.04.001